Poorer outcomes seen with generic tacrolimus

08/15/2008 | Doctor's Guide

Patients treated with Tenacrine, a generic version of tacrolimus, after their first kidney transplant had a greater likelihood of rejecting the organ than did those treated with Prograf, the nongeneric version, according to the findings of a three-year study. About twice as many patients on the generic version developed acute rejection. Children younger than 10 years and with heart disease had a greater probability of rejecting the organ regardless of which drug they were given.

View Full Article in:

Doctor's Guide

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC